Alpha-1 antitrypsin deficiency research and emerging treatment strategies: what’s down the road?

Franck F. Rahaghi

Abstract: Intravenous infusion of alpha-1 antitrypsin (AAT) was approved by the United States Food and Drug Administration (FDA) to treat emphysema associated with AAT deficiency (AATD) in 1987 and there are now several FDA-approved therapy products on the market, all of which are derived from pooled human plasma. Intravenous AAT therapy has proven clinical efficacy in slowing the decline of lung function associated with AATD progression; however, it is only recommended for individuals with the most severe forms of AATD as there is a lack of evidence that this treatment is effective in treating wild-type heterozygotes (e.g., PI*MS and PI*MZ genotypes), for which the prevalence may be much higher than previously thought. There are large numbers of individuals that are currently left untreated despite displaying symptoms of AATD. Furthermore, not all countries offer AAT augmentation therapy due to its expense and inconvenience for patients. More cost-effective treatments are now being sought that show efficacy for less severe forms of AATD and many new therapeutic technologies are being investigated, such as gene repair and other interference strategies, as well as the use of chemical chaperones. New sources of AAT are also being investigated to ensure there are enough supplies to meet future demand, and new methods of assessing response to treatment are being evaluated. There is currently extensive research into AATD and its treatment, and this chapter aims to highlight important emerging treatment strategies that aim to improve the lives of patients with AATD.

Keywords: alpha-1 antitrypsin, alpha-1 antitrypsin deficiency, biomarkers, cell transplantation, chemical chaperones, CRISPR-Cas9, epigenetics, gene repair, microRNA

Received: 19 November 2020; revised manuscript accepted: 8 April 2021.

Introduction

At present there is only one disease-modifying pharmacological intervention available specifically for the treatment of alpha-1 antitrypsin deficiency (AATD): intravenous (IV) infusion of alpha-1 antitrypsin (AAT). There are several products currently available in the United States (US) to treat emphysema in patients with AATD that have been approved by the US Food and Drug Administration, and there are three approved products currently available in Europe (Table 1). Each product is prepared from pooled human plasma. However, as discussed in previous chapters in this series of reviews, this IV AAT therapy has limitations for its use, such as cost implications and patient burden. Therefore, patients with AATD have substantial unmet needs and several new on-going developments are focusing on reducing patient inconvenience, while providing efficacy in decreasing morbidity and mortality. Following issues raised by patients on the need for a global registry, further information on comorbidities, natural history of the disease, risk factors for progression and the poor prognosis of lung disease, the European Alpha-1 Research Collaboration (EARCO) was created. The EARCO is a Clinical Research Collaboration of the European Respiratory Society, which will collaborate with the European Reference Network (ERN) for respiratory diseases (ERN-LUNG),
The ERN for hepatological diseases (ERN RARE-LIVER), and the registry of the Alpha-1 Liver Group. The aim of the collaboration is to bring together researchers, healthcare providers, patients, and industries to advance our understanding and improve the quality of life for patients with AATD.

The current chapter in this series of reviews on AATD aims to raise awareness of these current unmet needs and new therapy developments currently in the pipeline, including use of biomarkers to evaluate disease progression and treatment response to disease-modifying intervention. However, as AATD is a rare disease, it can be challenging to obtain conclusive data from small patient cohorts. Nevertheless, rare disease drug development is an area that is rapidly expanding and there is a trend between the increasing number of clinical trials and the increasing number of rare diseases being reported, with many technologies for treatment available. Several of these technologies are discussed herein with relation to their use within the field of AATD.

**Current treatment and unmet needs**

The only licensed treatment that has a disease-modifying effect on AATD progression is weekly IV infusion of plasma-derived AAT, which aims to delay the progression of emphysema, reduce exacerbation frequency, and improve patient quality of life. Further information on the current treatment recommendations for AATD can be found within the chapter of this review series authored by Barjaktarevic and Campos. However, not all countries have accepted AAT therapy. Current IV AAT therapy incurs significant annual healthcare costs, which exceed prior estimates reported in a 2003 study on cost effectiveness for patients with severe AATD. In the US, AAT therapy costs an

| Trade name | Availability | Specific activity and concentration |
|------------|--------------|------------------------------------|
| Aralast-NP | US           | ≥0.55 mg of AAT per mg of total protein; 20 mg/ml after reconstitution in provided diluent¹¹ |
| Glassia    | US, Canada, Australia, New Zealand | ≥0.7 mg of AAT per mg of total protein; provided in solution at 20 mg/ml¹² |
| Prolastin-Cb | US, Argentina, Colombia | ≥0.7 mg of AAT per mg of total protein; provided in solution at 50 mg/ml¹³ |
| Zemaira    | US           | ≥0.7 mg of AAT per mg of total protein; 50 mg/ml after reconstitution in provided diluent¹⁴ |
| Alfalastin | France       | 0.67 mg of AAT per mg of total protein; 33.33 mg/ml after reconstitution in provided diluent¹⁵ |
| Prolastin   | National licenses in EU with mutual recognition procedure | ≥0.35 mg of AAT per mg of total protein; 25 mg/ml after reconstitution in provided diluent² |
| Respreeza   | Countries within the EU | ≥0.7 mg of AAT per mg of total protein; 50 mg/ml after reconstitution in provided diluent¹⁶ |

* Aralast-NP is a newer preparation of a previously approved product, Aralast™.¹⁷
* Prolastin-C is a newer preparation of a previously approved product, Prolastin®.¹⁸
* Zemaira is marketed as Respreeza® in Europe.
* Prolastin is licensed in the member states of European Economic Area in Austria, Ireland, Italy, Germany, Greece, Poland, Portugal, and The Netherlands. Prolastin® is also marketed as Prolastina® in Denmark, Finland, Norway, Spain, and Sweden, and marketed as Pulmolast® in Belgium.

AAT, alpha-1 antitrypsin; EU, European Union; US, United States.

The table above provides information on the approved AAT therapy preparations available in the US and Europe, along with their specific activity and concentration. The table highlights the importance of understanding the availability and concentration of these therapies, which are essential for the treatment of AATD patients.
estimated US$82,000 per patient per year, excluding other out-of-pocket costs to the patient, such as visits to the physician and/or emergency department, inpatient hospital stays and other prescription drug costs. The mean annual out-of-pocket cost for all patients with AATD is approximately US$1875, with annual costs of US$4601 and US$1689 for IV AAT therapy users and non-users, respectively. As AAT therapy is lifelong, treatment is costly and is commonly used only to treat the most severe forms of AATD (patients with PI*ZZ and PI*Null genotypes). This treatment has also been shown to change imaging characteristics of AATD based on evidence from the RAPID program. However, patients with less severe forms of AATD (e.g., PI*MZ and PI*SZ genotypes) can still experience disease symptoms but are often left untreated. Furthermore, the prevalence of these intermediate forms of AATD is thought to be greater than initial estimates, suggesting that there are even more individuals who may possibly benefit from therapy that go untreated. There is a rationale to treat these patients once a more widely available therapy has shown efficacy.

At present, IV AAT therapy regimens can be inconvenient for patients due to the need for lifetime weekly infusions. Moreover, this therapy addresses only AATD-associated lung disease and does not treat extra-pulmonary manifestations such as liver disease, which is discussed in detail within the chapter by Patel and Teckman. Therefore, new cost-effective treatments are being sought that would not only be more convenient for patients, but also address the underlying genetic component of AATD, rather than simply slowing disease progression and reducing symptom severity. More cost-effective therapy may encourage further research, adoption of therapy by more countries, and allow treatment of patients with less severe forms of AATD who are currently untreated.

**Research and future treatments**

**Sourcing AAT**

Supply of pooled human plasma-derived AAT can be variable in purity and activity. Therefore, new methods of obtaining AAT are required to improve consistency and to ensure supplies are able to meet future therapy demands. The human AAT gene, **SERPINA1**, has been expressed successfully in bacteria, yeast, and mammalian cell lines, as well as in animal models but to date no therapeutic product has been licensed from these alternative sources. New products obtained via alternative methods would need to meet several requirements for licensing. New products should be clinically efficacious, safe, demonstrate good plasma half-life, and be cost-effective relative to current sources of AAT. Due to the potential risk of contamination with new and unknown pathogens from current plasma-derived AAT, recombinant versions of AAT (rAAT) are also an attractive alternative that is being widely investigated. Modified rAAT is currently being explored in fusion protein-based therapy to treat patients with AATD with the aim of offering superior clinical activity to plasma-derived AAT by maintaining plasma concentration with a less frequent, monthly, dosing regimen.

**Escherichia coli** is a readily available and common recombinant protein expression platform for a wide variety of proteins due to its fast growth kinetics, inexpensive growth media, and simplicity of transformation with exogenous DNA, despite its inability to glycosylate recombinant proteins. Lack of protein glycosylation in the **E. coli** expression system can affect rAAT activity, circulating half-life after infusion, and cause rAAT aggregation, as plasma-derived human AAT contains three glycosylation sites important for protein stability and protection from proteolysis and/or degradation. The lack of rAAT glycosylation could potentially be overcome by utilizing genetically modified **E. coli** that have proven to be 100% efficient in glycosylating rAAT.

Plant cell suspension systems are also emerging as a promising alternative for bioproduction of pharmaceutical agents, including AAT, and are able to express high yields of glycosylated rAAT in relatively short periods of time. However, there is currently a lack of regulatory approval for plant expression systems. Yeast systems are another attractive option for rAAT production due to their cost and time efficiency. Yeast systems may also be more advantageous over bacteria as they do not produce endotoxins and are able to provide some post-translational modifications, including glycosylation. However, a mammalian system would be ideal in expressing a
rAAT more akin to human AAT. Transduction of mammalian cell lines with a lentiviral gene delivery system can be successful in producing large amounts of recombinant human AAT but, unfortunately, mammalian expression systems are complex, costly, time-consuming and associated with limitations in protein yield.

Inhalation AAT therapy

Early studies have reported that, in addition to the expense and inconvenience of IV AAT therapy, only 2–3% of IV AAT reaches the lungs. Therefore, inhalation therapy has been studied in order to deliver AAT directly to the lungs; a method that has attracted a high level of interest from patients with AATD. A study from as far back as the late 1980s demonstrated that inhaled AAT can increase AAT levels in the lung epithelial lining fluid in patients with severe AATD (PI*ZZ) from 0.28 µM to 5.86 µM. Since then, little has been reported on aerosolized AAT therapy in patients with AATD, and IV AAT therapy has been the standard method of administration. However, as we are now looking to further improve the lives of patients with AATD, inhalation therapy is gaining more momentum.

In 2001, it was shown that more AAT reaches the lungs via inhalation than through the IV route (14.6% versus 2%, respectively), further confirming that inhalation therapy may be a more convenient route of AAT administration. It has also been suggested that inhalation therapy may lead to improved mobility and improved quality of life for patients who are currently restricted by the need for frequent IV AAT infusions. The improved delivery of AAT via the lungs may also reduce healthcare costs. However, there are concerns about clinical efficacy of inhalation as a delivery method because in 2019 a clinical trial suggested there was no associated reduction in exacerbation frequency. The randomized placebo-controlled clinical trial was conducted in 168 patients with AATD (PI*ZZ) and severe chronic obstructive pulmonary disease (COPD), who experienced frequent exacerbations. Results demonstrated that AAT inhalation therapy had no effect on the time to first exacerbation during 50 weeks of treatment. The time to the first moderate/severe exacerbation was a median of 112 days for patients receiving inhaled AAT and 140 days for placebo treatment. Furthermore, patients receiving AAT reported more treatment-related adverse events (such as dyspnea, cough, respiratory tract infection, and nausea) compared with placebo (57.5% versus 46.9%, respectively). Following improvements in the handling of the AAT and nebulizer, the safety profile of the AAT treatment group became similar to that of the placebo group, resembling the results reported in the IV AAT study (RAPID). Nevertheless, a prospective phase III trial is currently underway to determine the efficacy and safety of AAT inhalation therapy in patients with AATD. The trial is expected to end in 2023 and is being conducted in patients with AATD who have moderate airflow limitation [forced expiratory volume in 1 s (FEV₁) ≤50–80% of predicted] and an FEV₁/slow vital capacity ≤70%. At least 220 patients are expected to be enrolled in the study. After 4 weeks of practicing with the nebulizer, patients will be randomized to either 80 mg/day AAT inhalation or placebo for 104 weeks. During the study, inhaled AAT will be evaluated by lung function assessment via blood tests and computed tomography (CT) densitometry. Information on the utility of CT densitometry in AATD studies can be found in this series’ chapter on imaging in AATD by Huang et al.

Epigenetics and genetic modifiers

The variable nature of AATD and its strong influence by environmental exposures and lifestyle factors implicate a major role for epigenetic regulation in the pathophysiology of AATD. Epigenetic traits are stably heritable phenotypes resulting from changes in chromosomes without alterations in DNA sequence. DNA methylation is an epigenetic trait usually associated with silencing gene expression, and there is evidence of altered methylation patterns in patients with AATD, particularly in smokers. In a study of 316 patients with AATD (PI*ZZ), methylation of 16 methylation sites demonstrated significant association with ever-smoking and a younger age at smoking initiation, highlighting the harmful effect of smoking for patients with AATD. Examples of epigenetic changes that are affected by smoking are shown in Figure 1.

Cigarette smoke is particularly harmful in patients with severe AATD (e.g., PI*ZZ). Cigarette smoke induces oxidation of AAT and accelerates polymerization of mutant AAT,
inactivating the anti-elastase function whilst simultaneously creating a proinflammatory environment that reduces pulmonary defenses and increases neutrophil influx into the lungs. Blocking cigarette smoke-induced oxidation with N-acetyl cysteine, a potent antioxidant, has been shown to prevent oxidation-induced polymerization of mutant AAT, potentially suggesting a novel anti-oxidative therapeutic strategy for treating AATD.

Modifier genes have also been reported for AATD. Two examples of genes that have been shown to be associated with lung function phenotypes in patients with AATD are cholinergic receptor nicotinic alpha 3 subunit (CHRNA3), which encodes a ligand-gated ion channel involved in neurotransmission, and iron responsive element binding protein 2 (IREB2), an RNA-binding protein involved in iron homeostasis. In the AAT Genetic Modifiers Study, single nucleotide polymorphisms (SNPs) in both CHRNA3 and IREB2 were shown to be associated with different lung function phenotypes in individuals with AATD, all of whom had the PI*ZZ AATD genotype. The AAT Genetic Modifiers Study also suggested a potential sex-specific effect of these SNPs as they were significantly associated with lung function phenotypes in the male subgroup (p=0.02 and p=0.03 for CHRNA3 and IREB2, respectively), but not the female subgroup.

The vitamin D-binding protein (DBP) may also play a role in AATD. The DPG gene, group-specific complement (GC), is highly polymorphic, with three common variants and over 120 rare variants. One of these DBP variants, the GC2 variant, which is less able to activate macrophages, has been shown to be associated with a decreased risk of COPD (p=0.05). However, the same variant has been associated with an increased risk of bronchiectasis in patients with AATD (p=0.04). Further studies will be required to ascertain whether vitamin D supplementation will be beneficial for patients with AATD.

Whole exome sequencing (WES), a technique for sequencing all protein-coding regions of genes within the genome, has now enabled further identification of genes that may be involved in the development or suppression of AATD. In a study of four families with severe AATD (PI*ZZ or PI*Z/Q0Brescia), WES identified 14 genes in a recessive model (PI*Z homozygosity) and 21 genes in a dominant model (PI*Z heterozygosity) of AATD that influence the risk of AATD development or avoidance. Among these genes, of
particular interest was the rs3747517 variant of interferon-induced with helicase C domain 1 (IFIH1), a gene strongly associated with susceptibility to autoimmune diseases, such as type I diabetes and multiple sclerosis. However, a genome-wide association study (GWAS) of lung function has yet to be performed in patients with AATD. Such a study could potentially determine whether genetic factors of lung function in the general population overlap with those in AATD.

As the heterogeneity of lung function in AATD is partially attributable to genetics (which is further discussed in an earlier chapter of this review series), further discovery of genetic modifiers of lung disease via GWAS could provide a greater understanding of AATD’s variable clinical presentation.

Emerging treatments

Gene repair strategies. Gene repair technology, such as CRISPR-Cas9 [clustered regularly interspersed short palindromic repeats (CRISPR)] associated nuclease 9] is revolutionizing many areas of medical research, such as human immunodeficiency virus and hepatitis B virus infection, as well as monogenic diseases such as Duchenne muscular dystrophy. CRISPR, therefore, represents an exciting approach that could be key to solving both lung and liver consequences of AATD (Figure 2). In AATD mouse models, PI*ZZ mice show evidence of liver disease reversal upon successful gene editing via CRISPR, in addition to reduced mutant Z protein aggregation and restoration of modest levels of normal AAT expression.

Besides CRISPR-Cas9, another method of gene therapy is the use of recombinant adeno-associated viral (rAAV) vectors to deliver the normal AAT gene (SERPINA1) to patients with PI*ZZ AATD. In a phase I clinical trial, rAAV vectors expressing normal AAT protein were injected intra-muscularly into nine patients with the PI*ZZ genotype. The approach was associated with a positive safety profile and prolonged duration of
normal AAT protein expression; however, serum AAT levels were more than 200-fold below the putative therapeutic target of 11 µM. A phase II trial using a rAAV designed to generate a substantial increase in normal AAT expression still produced normal AAT levels below the therapeutic target. Together, these studies show that rAAV-AAT vectors require further improvements to achieve target AAT concentrations required for therapeutic success.

An alternative to vector-based delivery of SERPINA1 is to use cell transplantation. In a PI*ZZ mouse model, engrafted wild-type hepatocytes spontaneously proliferated preferentially over host hepatocytes, replacing them by 20–98%, and this repopulation was accelerated by injection of an adenovector-expressing hepatocyte growth factor. This method of hepatocyte transplantation could potentially be an effective therapy for patients with and without severe liver disease.

Human induced pluripotent stem cells (hiPSCs) derived from dermal fibroblasts from individuals with AATD are also being studied to advance the development of therapy for AATD. These cells have been used to generate patient-specific stem cell lines that have been differentiated into hepatocytes, enabling recapitulation of hepatic AAT protein folding to aid modeling of AATD’s pathological dysregulation of protein misfolding and therapeutic responses/toxicities to new pharmacological agents. hiPSCs have also been used in a proof-of-concept study on genetic correction, demonstrating that zinc finger nucleases in combination with the piggyBac gene editing technique can restore the normal structure, function, and secretion of AAT in subsequently derived hepatocytes, both in vitro and in vivo.

Chaperones and synthetics. As an alternative to gene therapy, use of chemical chaperones to improve proper folding of mutant AAT protein is being investigated. 4-phenyl butyrate (4PBA) was the most effective chemical chaperone in one study designed to increase the secretion of functionally active PI*ZZ AAT in a human cell culture model. The chemical chaperone was also well tolerated in PI*ZZ mice, consistently increasing serum AAT levels up to 50% of those in normal humans and mice. Furthermore, 4PBA is well tolerated in humans and therefore satisfies many of the criteria required for a potential chemoprophylactic tool for lung and liver injury in AATD. On this basis, a pilot in-human trial was conducted, but no effect on AAT secretion was detected, likely due to an inability to safely achieve the therapeutic levels of 4PBA described in the PI*ZZ mouse model. A major limitation of the chemical chaperone approach is the sheer mass of chemical chaperone required to be delivered to the hepatocyte endoplasmic reticulum.

In November 2019 a phase II trial was initiated to determine the efficacy and safety of facilitating proper folding of the PI*ZZ variant of AAT via oral delivery of an experimental protein chaperone (VX-814). The oral delivery route has the benefit of being a less invasive drug delivery method than IV administration and is also associated with good patient compliance. However, the VX-814 trial was terminated in October 2020 at the sponsor’s discretion as it was not feasible to safely reach targeted VX-814 exposure levels to provide a meaningful increase in levels of AAT.

Synthetic peptides are also being investigated for the treatment of AATD. A 6-mer peptide corresponding to the P7-2 sequence of the AAT reactive loop has been demonstrated to completely inhibit polymerization of the Z forms of AAT, without any inhibitory effect on the normal form of AAT. This molecule therefore has potential to prevent the intracellular accumulation of Z AAT within hepatocytes and therefore treat AATD-associated liver disease. However, this approach may result in the release of Z AAT proteins into the circulation and so would not address the need to increase levels of functional serum AAT; AAT replacement therapy would still be required.

Monoclonal antibodies have been developed to detect mutant conformations of AAT to help quantify levels of mutant AAT in biological samples and aid the development of small molecules to block polymerization. Intracellularly expressed antibody fragments (intrabodies) are emerging as one approach to modulate the function of targets in different intracellular compartments. One such intrabody is scFv4B12, a single-chain variable fragment of the 4B12 monoclonal antibody that has been shown to prevent intracellular polymerization of PI*ZZ AAT and increase its hepatic secretion, while retaining neutrophil elastase inhibitory function.
intrabody has been developed that can not only inhibit the intracellular polymerization of Z AAT but also, when bound to Z AAT, allows the protein to retain almost two-thirds of its inhibitory activity against neutrophil elastase (NE). The results with scFv4B12 KDEL have been demonstrated only in vitro so-far but provide another step forward in the use of intrabodies for AATD treatment.

Finding a molecule that can bind to Z AAT, prevent polymerization, and restore NE inhibitory function both in vitro and in vivo is challenging, but the use of structure-based drug design is being employed to identify molecules that can bind to Z AAT in such a way to achieve this desired function. In silico ligand screening of 1.2 million small molecules has identified six compounds that reduced Z AAT polymer formation in vitro and 10 compounds that completely blocked Pi*ZZ polymerization. The lead compound identified in this study, CG, was also found to be highly selective and non-promiscuous, and therefore less likely to have unwanted off-target effects.

Interference strategies. Further strategies for future AATD therapy include several methods that interfere with AATD pathogenesis. RNA interference (RNAi) strategies include small interfering RNA molecules that can disrupt mutant AAT polymerization/degradation and manipulate autophagy for the treatment of liver disease in patients with AATD. Several applications of RNAi technology are currently underway with the aim of preventing synthesis of the Z form of AAT to prevent toxic hepatic accumulation and subsequent liver injury. Phase I/II and phase II/III clinical trials utilizing RNA silencing to prevent Z AAT protein synthesis as a therapy for AATD are now underway in Europe, and the US. These trials are expected to end in 2022 and 2023, respectively.

As discussed within the first chapter of this review series by Tejwani and Stoller, the main damage inflicted on the AATD patient’s lung is through a proinflammatory imbalance of proteases, NE in particular. NE is one of the major proteases involved in a range of conditions, such as community-acquired and ventilator-associated pneumonia, acute lung injury and acute respiratory distress syndrome, exacerbated COPD, cystic fibrosis, and bronchiectasis. In AATD, the involvement of NE and other proteases is rather complex, and the inability of IV AAT therapy to completely block emphysema progression in AATD suggests that alternative processes play a role in disease progression. Nevertheless, NE inhibitors are being investigated for treatment of AATD. As a proof-of-concept study to investigate the mechanistic effect and the safety of an orally administered NE inhibitor, Pi*ZZ/Pi*SZ/ Pi*Null patients in the US are being treated over a period of 12 weeks, with an additional aim of investigating whether the treatment can reduce lung damage and slow disease progression. The study is expected to be completed in August 2021. However, the role that other enzymes play in AATD-specific inflammatory processes warrants further investigation.

Biomarkers
Along with research into new treatments for AATD, there is also extensive research into new ways of testing AATD treatment efficacy, which is currently measured in the clinic using spirometry and CT-based lung density assessment. In addition, biomarkers can also be reliable measures of treatment efficacy. Serum gamma glutamyl transferase (GGT) is frequently used as a biomarker of liver disease but may be particularly useful as a biomarker in AATD as it has been shown to be widely elevated in patients with the Pi*ZZ genotype. The relationship between serum GGT, lung disease, liver disease, and mortality in patients with AATD is independently associated with airflow obstruction and mortality. Although not specific to AATD, in patients with COPD, several markers such as chemokine (C-C motif) ligand 18 (CCL-18), C-reactive protein, fibrinogen, interleukin (IL)-6, IL-8, surfactant protein D, and white blood cell counts are all elevated in non-survivors compared with survivors, and are specifically associated with patient mortality over 3 years. In addition, elevated levels of plasma fibrinogen, another glycoprotein synthesized in hepatocytes, is associated with a risk of COPD and other inflammatory diseases. In AATD specifically, a fibrinogen degradation product (Aα-Val360) has been found to be increased in patients with AATD, and positively correlated with spirometric severity of AATD lung disease, as well as sputum elastase activity in acute exacerbations. Furthermore, Aα-Val360 levels are decreased in patients receiving IV AAT therapy and it is, therefore, a potential biomarker of treatment response.
Levels of desmosine and isodesmosine (DES/IDES; markers of elastin degradation) are also elevated in AATD and non-AATD COPD and, like Aα-Val⁵⁴¹, can be utilized as biomarkers of AAT therapy response. DES/IDES plasma levels have been shown to be significantly reduced in patients receiving AAT therapy (p<0.001)⁹⁵ and in bronchoalveolar lavage fluid from patients receiving double dose AAT therapy (p=0.050).⁹⁶ Levels of proteinase 3 (PR3) could be another potential biomarker for AATD. PR3, like AAT, is a serine proteinase and is released by neutrophil azurophilic granules along with NE following neutrophil activation.⁹⁷ Cleavage of fibrinogen with PR3 produces several fragments, one of which, Aα-Val⁵⁴¹, can be detected in plasma from patients with AATD.⁹⁸ An enzyme-linked immunosorbent assay (ELISA) for Aα-Val⁵⁴¹ performed in sera from patients with AATD (PI*ZZ and PI*SZ) has shown that levels of Aα-Val⁵⁴¹ are much higher (~17 times higher) than those of Aα-Val⁵⁴⁶.⁹⁸ and therefore it may be a more sensitive biomarker than Aα-Val⁵⁴⁶. The Aα-Val⁵⁴¹ ELISA was also sensitive to augmentation therapy and therefore also represents a potential biomarker for AAT dose-ranging studies.⁹⁸

The tumor necrosis factor-alpha (TNF-α) gene represents a potential genetic biomarker for AATD. TNF-α is a pro-inflammatory cytokine that has been implicated in the pathophysiology of several pulmonary diseases, such as asthma, chronic bronchitis, and COPD.⁹⁹ Levels of inflammation have been demonstrated to be higher in patients with AATD compared with non-AATD-related COPD,¹⁰⁰ and AAT has also been shown to down-regulate TNF-α gene expression.¹⁰¹ Wood and colleagues hypothesized that TNF-α may play a role in AATD; however, they found no association between TNF-α levels and disease severity as measured by lung function assessment or high-resolution CT in 424 individuals with PI*ZZ AATD genotype.¹⁰² Instead, Wood et al., demonstrated that a single nucleotide polymorphism in the TNF-α gene (rs361525) was significantly associated with patients with AATD and chronic bronchitis (p=0.01).¹⁰² SNPs in SERPINA1 may therefore not be the only genetic variants associated with AATD. An overview of the SNPs in SERPINA1 variants associated with AATD is further described by Foil⁹³ in a separate chapter of this review series.

Circulating free light chains (FLCs) of antibodies produced during an immune response are markers of adaptive immune activation and are clinically relevant biomarkers of several autoimmune diseases.¹⁰³ Increased FLC levels have also been reported in asthma and COPD.¹⁰⁴,¹⁰⁵ In AATD, patients that have chronically colonized sputum cultures have significantly higher FLC levels compared with patients with no positive cultures (p=0.008).¹⁰⁶ Furthermore, in severe AATD, increased FLC levels were significantly associated with mortality (p=0.001), indicating that FLCs could play a role in the risk-stratification of patients requiring more intensive monitoring and disease management.¹⁰⁶

MicroRNAs (miRNAs) primarily act as regulatory molecules for gene expression in normal physiology, but also play important roles in pathological processes in a wide variety of diseases, such as cancer,¹⁰⁷ cardiovascular disease,¹⁰⁸ rheumatic diseases,¹⁰⁹ and age-related diseases, such as osteoarthritis.¹¹⁰ In a preliminary study, nine miRNAs were found to be significantly down-regulated in patients with AATD, which may provide the opportunity for miRNA-based monitoring of lung and liver disease associated with AATD.¹¹¹

Conclusions
Alternatives to IV AAT therapy with different modes of action are being investigated. In the short-term, use of chaperones could be a promising new treatment, providing that researchers can overcome the current requirement for large quantities of chaperones for an effective outcome. Use of in silico ligand screening may also prove to be a valuable tool in designing new molecules that interfere with AATD pathogenesis. In the long-term, hepatocyte replacement and CRISPR strategies would be greatly beneficial, as these methods would allow simultaneous treatment of both lung and liver disease associated with AATD. There are also new biomarkers being identified that may indicate levels of disease progression and response to therapy. However, it may be several years before any new therapies enter the market. At present, IV AAT therapy remains the only available disease-modifying and well tolerated pharmacological intervention for AATD.

Author contributions
FFR contributed to the writing of the manuscript, reviewed the manuscript, and approved the manuscript for submission.
Conflict of interest statement
FFR is a consultant, speaker, and researcher for Takeda and Grifols, and a consultant for CSL Behring.

Acknowledgments
Medical writing assistance was provided by Ben McDermott and Steven Foster of Meridian HealthComms Ltd., Plumley, UK, in accordance with good publication practice (GPP3), funded by CSL Behring.

References
1. Mohanka M, Khemasuwan D and Stoller JK. A review of augmentation therapy for alpha-1 antitrypsin deficiency. Expert Opin Biol Ther 2012; 12: 685–700.
2. Thabut G and Corda L. Epidemiology, diagnosis and available treatment for alpha 1 antitrypsin deficiency-related emphysema in Europe. Eur Respir Pulm Dis 2018; 4: 25.
3. Tejwani V and Stoller JK. The spectrum of clinical sequela associated with alpha-1 antitrypsin deficiency. Ther Adv Chronic Dis 2021; 12(2S): 3–11.
4. Barjaktarevic I and Campos M. Management of lung disease in alpha-1 antitrypsin deficiency: what we do and what we don’t know. Ther Adv Chronic Dis 2021; 12(2S): 49–63.
5. Sandhaus RA, Strange C, Zanichelli A, et al. Improving the lives of patients with alpha-1 antitrypsin deficiency. Int J COPD 2020; 15: 3313–3322.
6. Miravitlles M, Chorostowska-Wynimko J, Ferrarotti I, et al. The European Alpha-1 Research Collaboration (EARCO): a new ERS Clinical Research Collaboration to promote research in alpha-1 antitrypsin deficiency. Eur Respir J 2019; 53: 1900138.
7. Humbert M and Wagner TO. Rare respiratory diseases are ready for primetime: from Rare Disease Day to the European Reference Networks. Eur Respir J 2017; 49: 1700085.
8. Wanner A, Groft SC, Teagarden JR, et al. Clinical trial design for alpha-1 antitrypsin deficiency: a model for rare diseases. Chronic Obstr Pulm Dis 2015; 2: 177–190.
9. Sakate R, Fukagawa A, Takagaki Y, et al. Trends of clinical trials for drug development in rare diseases. Curr Clin Pharmacol 2018; 13: 199–208.
10. Tambuyzer E, Vandendriessche B, Austin CP, et al. Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. Nat Rev Drug Discov 2020; 19: 93–111.
11. US Food and Drug Administration. Aralast NP (alpha1-proteinase inhibitor [human]). Baxter Healthcare Corporation, https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/aralast-np (2007, accessed 1 February 2021)
12. US Food and Drug Administration. GLASSIA (alpha1-proteinase inhibitor [human]). Kamada Ltd., https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/glassia (2010, accessed 2 February 2021)
13. US Food and Drug Administration. Prolastin®-C (alpha1-proteinase inhibitor [human]). Talecris Biotherapeutics, Inc., https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/prolastin-c (1987, accessed 2 February 2021)
14. US Food and Drug Administration. Zemaira (alpha1-proteinase inhibitor [human]). Aventis Behring LLC, https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/zemaira (2003, accessed 2 February 2021)
15. Agence Nationale de Sécurité du Médicament et des Produits de Santé. Directory of pharmaceutical specialties. ALFALASTIN, http://agence-prd.ansm.sante.fr/php/ecodex/ extrait.php?specid=60153239 (2005, accessed 19 February 2021)
16. European Medicines Agency. Respreeza (alpha1-proteinase inhibitor [human]). CSL Behring GmbH, https://www.ema.europa.eu/en/medicines/human/EPAR/respreeza (2015, accessed 2 February 2021)
17. US Food and Drug Administration. Aralast (alpha1-proteinase inhibitor [human]). Baxter Healthcare Corporation, https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/aralast (2002, accessed 1 February 2021)
18. US Food and Drug Administration. Prolastin® (alpha1-proteinase inhibitor [human]). Talecris Biotherapeutics, Inc., https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/prolastin (2005, accessed 2 February 2021)
19. Chapman KR, Burdon JGW, Piitulainen E, et al. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 386: 360–368.
Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). *Lancet Respir Med* 2017; 5: 51–60.

Reduction of severe exacerbations and hospitalization-derived costs in α1-antitrypsin-deficient patients treated with α1-antitrypsin augmentation therapy. *Ther Adv Respir Dis* 2012; 6: 67–78.

Cost-effectiveness analysis of augmentation therapy for severe α1-antitrypsin deficiency. *Am J Respir Crit Care Med* 2003; 167: 1387–1392.

Costs of medical care among augmentation therapy users and non-users with α1 antitrypsin deficiency in the United States. *Chronic Obstr Pulm Dis* 2019; 6: 6–16.

Prevalence of α1-antitrypsin deficiency alleles PI*S and PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: a comprehensive review. *Ther Adv Respir Dis* 2012; 6: 277–295.

Liver disease with unknown etiology: have you ruled out alpha-1 antitrypsin deficiency? *Ther Adv Chronic Dis* 2021; 12(25): 25–32.

A pilot study comparing the purity, functionality and isoform composition of alpha-1-proteinase inhibitor (human) products. *Curr Med Res Opin* 2005; 21: 877–889.

High-level production of biologically active human alpha 1-antitrypsin in *Escherichia coli*. *Proc Natl Acad Sci USA* 1984; 81: 669–673.

Production and recovery of recombinant protease inhibitor α1-antitrypsin. *Enzyme Microb Technol* 2001; 29: 611–620.

Expression of recombinant alpha-1 antitrypsin in CHO and COS-7 cell lines using lentiviral vector. *Iran J Biotechnol* 2009; 7: 148–156.

Lentiviral expression system for the purification of secreted proteins from human cell cultures. *BMC Biotechnol* 2016; 16: 66.

Therapeutic genome editing with CRISPR/Cas9 in a humanized mouse model ameliorates α1 antitrypsin deficiency phenotype. *EBioMedicine* 2018; 29: 104–111.

Amelioration of alpha-1 antitrypsin deficiency diseases with genome editing in transgenic mice. *Hum Gene Ther* 2018; 29: 861–873.

National Institutes of Health. Phase 1 study to assess the safety, PK and PD of INBRX-101 in adults with alpha-1 antitrypsin deficiency (rhAAT-Fc), https://clinicaltrials.gov/ct2/show/NCT03815396 (2019, accessed 29 January 2021)

Recombinant protein expression in *Escherichia coli*: advances and challenges. *Front Microbiol* 2014; 5: 172.

Recombinant human alpha-1 proteinase inhibitor: towards therapeutic use. *Amino Acids* 2006; 30: 317–332.

The role and importance of glycosylation of acute phase proteins with focus on alpha-1 antitrypsin in acute and chronic inflammatory conditions. *J Proteome Res* 2014; 13: 3131–3143.

Increased glycosylation efficiency of recombinant proteins in *Escherichia coli* by auto-induction. *Biochem Biophys Res Commun* 2017; 485: 138–143.
challenges and opportunities. *Plants People Planet* 2020; 2: 121–132.

42. Arjmand S, Bidram E, Lotfi AS, *et al.* Expression and purification of functionally active recombinant human alpha 1-antitrypsin in methylotrophic yeast *Pichia pastoris*. *Avicenna J Med Biotechnol* 2011; 3: 127–134.

43. Mead EJ, Chiverton LM, Smales CM, *et al.* Identification of the limitations on recombinant gene expression in CHO cell lines with varying luciferase production rates. *Biotechnol Bioeng* 2009; 102: 1593–1602.

44. Hubbard RC, Sellers S, Czerski D, *et al.* Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency. *JAMA* 1988; 260: 1259–1264.

45. Monk R, Graves M, Williams P, *et al.* Inhaled alpha 1-antitrypsin: gauging patient interest in a new treatment. *COPD* 2013; 10: 411–415.

46. Hubbard RC, Brantly ML, Sellers SE, *et al.* Anti-neutrophil-elastase defenses of the lower respiratory tract in α1-antitrypsin deficiency directly augmented with an aerosol of α1-antitrypsin. *Am Intern Med* 1989; 111: 206–212.

47. Kropp J, Wencker M, Hotze A, *et al.* Inhalation of [123I]alpha1-protease inhibitor: toward a new therapeutic concept of alpha1-protease inhibitor deficiency? *J Nucl Med* 2001; 42: 744–751.

48. Stolk J, Tov N, Chapman KR, *et al.* Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD. *Eur Respir J* 2019; 54: 1900673.

49. National Institutes of Health. Evaluate efficacy and safety of “Kamada-AAT for inhalation” in patients with AATD (InnovAATe), https://clinicaltrials.gov/ct2/show/NCT04204252 (2019, accessed 7 April 2020)

50. Huang YCT, Wencker M and Driehuys B. Imaging in alpha 1-antitrypsin deficiency: a window into the disease. *Ther Adv Chronic Dis* 2021; 12(2S): 13–23.

51. Berger SL, Kouzarides T, Shiekhattar R, *et al.* An operational definition of epigenetics. *Genes Dev* 2009; 23: 781–783.

52. Moore LD, Le T and Fan G. DNA methylation and its basic function. *Neuropsychopharmacology* 2013; 38: 23–38.

53. Siedlinski M, Klanderman B, Sandhaus RA, *et al.* Association of cigarette smoking and CRP levels with DNA methylation in α1-antitrypsin deficiency. *Epigenetics* 2012; 7: 720–728.

54. Hu N and Ren J. Epigenetics in smoking-associated cardiovascular diseases. *React Oxyg Species (Apex)* 2016; 2: 396–403.

55. Alam S, Li Z, Janciauskiene S, *et al.* Oxidation of Z α1 antitrypsin by cigarette smoke induces polymerization. *Am J Respir Cell Mol Biol* 2011; 45: 261–269.

56. Kim WJ, Wood AM, Barker AF, *et al.* Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency. *Respir Res* 2012; 13: 16.

57. Cleve H and Constans J. The mutants of the vitamin-D-binding protein: more than 120 variants of the GC/DBP system. *Vox Sang* 1988; 54: 215–225.

58. Wood AM, Bassford G, Webster D, *et al.* Vitamin D-binding protein contributes to COPD by activation of alveolar macrophages. *Thorax* 2011; 66: 205–210.

59. Rigobello C, Baraldo S, Tiné M, *et al.* Exome sequencing reveals immune genes as susceptibility modifiers in individuals with α1-antitrypsin deficiency. *Sci Rep* 2019; 9: 13088.

60. Looney BM, Xia CQ, Concannon P, *et al.* Effects of type 1 diabetes-associated IFIH1 polymorphisms on MDA5 function and expression. *Curr Diab Rep* 2015; 15: 96.

61. Enevold C, Oturai AB, Sørensen PS, *et al.* Multiple sclerosis and polymorphisms of innate pattern recognition receptors TLR1-10, NOD1-2, DDX58, and IFIH1. *J Neuroimmunol* 2009; 2021: 125–131.

62. Hobbs BD and Cho MH. Why is disease penetration so variable? Role of genetic modifiers of lung function in alpha-1 antitrypsin deficiency. *Chronic Obstr Pulm Dis* 2020; 7: 214–223.

63. Foil KE. Variants of SERPINA1 and the increasing complexity of testing for alpha-1 antitrypsin deficiency. *Ther Adv Chronic Dis* 2021; 12(2S): 33–48.

64. Dai W-J, Zhu L-Y, Yan Z-Y, *et al.* CRISPR-Cas9 for in vivo gene therapy: promise and hurdles. *Mol Ther Nucleic Acids* 2016; 5: e349.

65. Stephens CJ, Kashentseva E, Everett W, *et al.* Targeted in vivo knock-in of human alpha-1-antitrypsin cDNA using adenoviral delivery of CRISPR/Cas9. *Gene Ther* 2018; 25: 139–156.

66. Brantly ML, Chulay JD, Wang L, *et al.* Sustained transgene expression despite T
lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. *Proc Natl Acad Sci USA* 2009; 106: 16363–16368.

67. Flotte TR, Trapnell BC, Humphries M, et al. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results. *Hum Gene Ther* 2011; 22: 1239–1247.

68. Ding J, Yannam G, Roy-Chowdhury N, et al. Spontaneous hepatic repopulation in transgenic mice expressing mutant human α1-antitrypsin by wild-type donor hepatocytes. *J Clin Invest* 2011; 121: 1930–1934.

69. Rashid ST, Corbineau S, Hannan N, et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. *J Clin Invest* 2010; 120: 3127–3136.

70. Wilson AA, Ying L, Liesa M, et al. Emergence of a stage-dependent human liver disease signature with directed differentiation of alpha-1 antitrypsin-deficient iPS cells. *Stem Cell Rep* 2015; 4: 873–885.

71. Yusa K, Rashid ST, Strick-Marchand H, et al. Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. *Nature* 2011; 478: 391–394.

72. Burrows JA, Willis LK and Perlmutter DH. Chemical chaperones mediate increased secretion of mutant α1-antitrypsin (α1-AT) Z; a potential pharmacological strategy for prevention of liver injury and emphysema in α1-AT deficiency. *Proc Natl Acad Sci USA* 2000; 97: 1796–1801.

73. Teckman JH. Lack of effect of oral 4-phenylbutyrate on serum alpha-1-antitrypsin in patients with alpha-1-antitrypsin deficiency: a preliminary study. *J Pediatr Gastroenterol Nutr* 2004; 39: 34–37.

74. Greene CM, Marciniak SJ, Teckman J, et al. α1-Antitrypsin deficiency. *Nat Rev Dis Primers* 2016; 2: 16051.

75. National Institutes of Health. Evaluation of the efficacy and safety of VX-814 in subjects with the PiZZ genotype, [https://clinicaltrials.gov/ct2/show/NCT04167345](https://clinicaltrials.gov/ct2/show/NCT04167345) (2019, accessed 18 February 2020).

76. Sastry SV, Nyshadham JR and Fix JA. Recent technological advances in oral drug delivery: a review. *Pharm Sci Technol Today* 2000; 3: 138–145.

77. Vertex Pharmaceuticals Incorporated. Vertex provides update on its clinical programs targeting alpha-1 antitrypsin deficiency. Business Wire, [https://www.businesswire.com/news/home/20201014005787/en/](https://www.businesswire.com/news/home/20201014005787/en/) (2020, accessed 29 March 2021).

78. Mahadeva R, Dafforn TR, Carrell RW, et al. 6-mer peptide selectively anneals to a pathogenic serpin conformation and blocks polymerization. Implications for the prevention of Z alpha(1)-antitrypsin-related cirrhosis. *J Biol Chem* 2002; 277: 6771–6774.

79. Miranda E, Pérez J, Ekeowa UI, et al. A novel monoclonal antibody to characterize pathogenic polymers in liver disease associated with alpha1-antitrypsin deficiency. *Hepatology* 2010; 52: 1078–1088.

80. Tan L, Perez J, Mela M, et al. Characterising the association of latency with α(1)-antitrypsin polymerisation using a novel monoclonal antibody. *Int J Biochem Cell Biol* 2015; 58: 81–91.

81. Cardinale A and Biocca S. Gene-based antibody strategies for prion diseases. *Int J Cell Biol* 2013; 2013: 710406.

82. Ordóñez A, Pérez J, Tan L, et al. A single-chain variable fragment intrabody prevents intracellular polymerization of Z α1-antitrypsin while allowing its antiproteinase activity. *FASEB J* 2015; 29: 2667–2678.

83. Mallya M, Phillips RL, Saldanha SA, et al. Small molecules block the polymerization of Z alpha1-antitrypsin and increase the clearance of intracellular aggregates. *J Med Chem* 2007; 50: 5357–5363.

84. National Institutes of Health. A study of DCR-A1AT in healthy adult volunteers and patients with A1ATD-associated liver disease, [https://clinicaltrials.gov/ct2/show/NCT04174118](https://clinicaltrials.gov/ct2/show/NCT04174118) (2019, accessed 18 February 2020).

85. National Institutes of Health. Safety, tolerability and effect on liver histologic parameters of ARO-AAT (SEQUOIA), [https://clinicaltrials.gov/ct2/show/results/NCT03945292](https://clinicaltrials.gov/ct2/show/results/NCT03945292) (2019, accessed 18 February 2020).

86. Polverino E, Rosales-Mayor E, Dale GE, et al. The role of neutrophil elastase inhibitors in lung diseases. *Chest* 2017; 152: 249–262.

87. Stockley RA. Alpha-1 antitrypsin deficiency: have we got the right proteinase? *Chronic Obstr Pulm Dis* 2020; 7: 163–171.

88. National Institutes of Health. Alvelestat (MPH996) for the treatment of ALpha-1 ANTitrypsin Deficiency (ATALANTA), [https://clinicaltrials.gov/ct2/show/NCT03679598](https://clinicaltrials.gov/ct2/show/NCT03679598) (2018, accessed 18 February 2020).
89. Brantly ML, Lascano JE and Shahmohammadi A. Intravenous alpha-1 antitrypsin therapy for alpha-1 antitrypsin deficiency: the current state of the evidence. *Chronic Obstr Pulm Dis* 2019; 6: 100–114.

90. Holme J, Dawkins PA, Stockley EK, *et al.* Studies of gamma-glutamyl transferase in alpha-1 antitrypsin deficiency. *COPD* 2010; 7: 126–132.

91. Celli BR, Locantore N, Yates J, *et al.* Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2012; 185: 1065–1072.

92. Duvoix A, Dickens J, Haq I, *et al.* Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. *Thorax* 2013; 68: 670–676.

93. Miller BE, Tal-Singer R, Rennard SI, *et al.* Plasma fibrinogen qualification as a drug development tool in chronic obstructive pulmonary disease. Perspective of the chronic obstructive pulmonary disease biomarker qualification consortium. *Am J Respir Crit Care Med* 2016; 193: 607–613.

94. Carter RJ, Mumford RA, Treonze KM, *et al.* The fibrinogen cleavage product Aα1-Val360, a specific marker of neutrophil elastase activity in vivo. *Thorax* 2011; 66: 686–691.

95. Ma S, Lin YY, Cantor JO, *et al.* The effect of alpha-1 protease inhibitor (A1PI) on biomarkers of elastin degradation in alpha-1 antitrypsin deficiency: an analysis of the RAPID/RAPID extension trials. *Chronic Obstr Pulm Dis* 2016; 4: 34–44.

96. Campos MA, Geraghty P, Holt G, *et al.* The biological effects of double-dose alpha-1 antitrypsin augmentation therapy: a pilot clinical trial. *Am J Respir Crit Care Med* 2019; 200: 318–326.

97. Kuckleburg CJ and Newman PJ. Neutrophil proteinase 3 acts on protease-activated receptor-2 to enhance vascular endothelial cell barrier function. *Arterioscler Thromb Vasc Biol* 2013; 33: 275–284.

98. Newby PR, Crossley D, Crisford H, *et al.* A specific proteinase 3 activity footprint in α1-antitrypsin deficiency. *ERJ Open Res* 2019; 5: 00095–002019.

99. Mukhopadhyay S, Hoidal JR and Mukherjee TK. Role of TNFα in pulmonary pathophysiology. *Respir Res* 2006; 7: 125.

100. Hill AT, Campbell EJ, Bayley DL, *et al.* Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with α1-antitrypsin deficiency (PiZ). *Am J Respir Crit Care Med* 1999; 160: 1968–1975.

101. Lockett AD, Kimani S, Ddungu G, *et al.* α1-Antitrypsin modulates lung endothelial cell inflammatory responses to TNF-α. *Am J Respir Cell Mol* 2013; 49: 143–150.

102. Wood AM, Simmonds MJ, Bayley DL, *et al.* The TNFalpha gene relates to clinical phenotype in alpha-1-antitrypsin deficiency. *Respir Res* 2008; 9: 52.

103. Hutchison CA and Landgren O. Polyclonal immunoglobulin free light chains as a potential biomarker of immune stimulation and inflammation. *Clin Chem* 2011; 57: 1387–1389.

104. Braber S, Thio M, Blokhuis BR, *et al.* An association between neutrophils and immunoglobulin free light chains in the pathogenesis of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2012; 185: 817–824.

105. Kraneveld AD, Kool M, van Houwelingen AH, *et al.* Elicitation of allergic asthma by immunoglobulin free light chains. *Proc Natl Acad Sci USA* 2005; 102: 1578–1583.

106. Hampson JA, Stockley RA and Turner AM. Free light chains: potential biomarker and predictor of mortality in alpha-1-antitrypsin deficiency and usual COPD. *Respir Res* 2016; 17: 34.

107. Shin VY and Chu K-M. MiRNA as potential biomarkers and therapeutic targets for gastric cancer. *World J Gastroenterol* 2014; 20: 10432–10439.

108. Vegeter EL, van der Meer P, de Windt LJ, *et al.* MicroRNAs in heart failure: from biomarker to target for therapy. *Eur J Heart Fail* 2016; 18: 457–468.

109. Alevizos I and Illei GG. MicroRNAs as biomarkers in rheumatic diseases. *Nat Rev Rheumatol* 2010; 6: 391–398.

110. Balaskas P, Golan-Jekh-Whysall K, Clegg P, *et al.* MicroRNA profiling in cartilage ageing. *Int J Genomics* 2017; 2017: 2713725.

111. Dasi F, Pastor S, Mata M, *et al.* Circulating microRNAs as potential biomarkers in alpha-1 antitrypsin deficiency patients. *Eur Respir J* 2014; 44: P2038.